RSLS Key Statistics, Chart & Performance
The current stock price of RSLS is 3.92 USD. In the past month the price increased by 37.54%. In the past year, price decreased by -98.49%.
RSLS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Related stock screener links
About RSLS
Company Profile
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Company Info
RESHAPE LIFESCIENCES INC
1001 Calle Amanecer
San Clemente CALIFORNIA 92673 US
CEO: Andrew Rasdal
Employees: 17
Phone: 19494296680
RESHAPE LIFESCIENCES INC / RSLS FAQ
What does RSLS do?
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
What is the stock price of RESHAPE LIFESCIENCES INC today?
The current stock price of RSLS is 3.92 USD. The price increased by 22.5% in the last trading session.
Does RSLS stock pay dividends?
RSLS does not pay a dividend.
How is the ChartMill rating for RESHAPE LIFESCIENCES INC?
RSLS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is RESHAPE LIFESCIENCES INC (RSLS) stock traded?
RSLS stock is listed on the Nasdaq exchange.
RSLS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RSLS. When comparing the yearly performance of all stocks, RSLS is a bad performer in the overall market: 99.02% of all stocks are doing better.
RSLS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RSLS. The financial health of RSLS is average, but there are quite some concerns on its profitability.
RSLS Financial Highlights
Over the last trailing twelve months RSLS reported a non-GAAP Earnings per Share(EPS) of -212.11. The EPS increased by 93.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.42% | ||
| ROE | -281.54% | ||
| Debt/Equity | 0 |
RSLS Forecast & Estimates
For the next year, analysts expect an EPS growth of 20% and a revenue growth 20% for RSLS